Clinical Trial Update: Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating panobinostat in combination with daratumumab, bortezomib, and dexamethasone for relapsed/refractory multiple myeloma has been terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• Panobinostat (Panobinostat)

Snippet

Sponsor: Abdullah Khan | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: TERMINATED